Consolidated Statement Of Changes In Equity

Nxera Pharma Co., Ltd. - Filing #7272710

Concept As at
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
As at
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
As at
2024-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
Consolidated statement of changes in equity
Statement of changes in equity
Net assets
233,000,000 JPY
-14,621,000,000 JPY
35,289,000,000 JPY
68,055,000,000 JPY
47,172,000,000 JPY
-3,000,000 JPY
-15,000,000 JPY
67,837,000,000 JPY
0 JPY
235,000,000 JPY
46,807,000,000 JPY
65,200,000,000 JPY
-16,765,000,000 JPY
64,965,000,000 JPY
34,924,000,000 JPY
-1,000,000 JPY
-1,000,000 JPY
57,544,000,000 JPY
29,452,000,000 JPY
57,306,000,000 JPY
-5,000,000 JPY
41,335,000,000 JPY
-13,480,000,000 JPY
243,000,000 JPY
Changes during period
Issuance of new shares
730,000,000 JPY
365,000,000 JPY
730,000,000 JPY
365,000,000 JPY
10,944,000,000 JPY
5,472,000,000 JPY
10,944,000,000 JPY
5,472,000,000 JPY
Net changes in items other than shareholders' equity
-2,000,000 JPY
-17,000,000 JPY
-15,000,000 JPY
-8,000,000 JPY
-3,000,000 JPY
5,000,000 JPY
Total changes during period
-2,000,000 JPY
-2,000,000 JPY
2,144,000,000 JPY
2,855,000,000 JPY
365,000,000 JPY
2,872,000,000 JPY
-15,000,000 JPY
365,000,000 JPY
7,659,000,000 JPY
5,472,000,000 JPY
-3,285,000,000 JPY
0 JPY
-8,000,000 JPY
7,656,000,000 JPY
5,472,000,000 JPY
5,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.